Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53
about
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncologyHexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaApplications of metabolomics in cancer researchHexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapyDichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerConserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarraysHypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesisMetabolic, autophagic, and mitophagic activities in cancer initiation and progressionRole of the p53 tumor suppressor in metabolismPancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parametersThe role of the p53 tumor suppressor in metabolism and diabetesRAS oncogenes: weaving a tumorigenic webGlycolysis inhibition for anticancer treatmentpO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puTumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.Tumor suppression and potentiation by manipulation of pp32 expression.p53: exercise capacity and metabolism.TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells.Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds.Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.p53, aerobic metabolism, and cancer.Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational statusRapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplateThe role of metabolic therapy in treating glioblastoma multiforme.Identification of proteins interacting with lactate dehydrogenase in claw muscle of the porcelain crab Petrolisthes cinctipes.Altered glucose metabolism in Harvey-ras transformed MCF10A cellssiRNA Screening Identifies the Host Hexokinase 2 (HK2) Gene as an Important Hypoxia-Inducible Transcription Factor 1 (HIF-1) Target Gene in Toxoplasma gondii-Infected CellsAlterations of metabolic genes and metabolites in cancer.p63 supports aerobic respiration through hexokinase II.Metabolic regulation of oxygen and redox homeostasis by p53: lessons from evolutionary biology?The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolismGenetic insights into OXPHOS defect and its role in cancerPhospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistanceMitochondria and cancer: Warburg addressed.Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense.delta-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profilesHexokinase 2 is a determinant of neuroblastoma metastasis
P2860
Q21129303-A78B0CC6-B7BB-444E-922F-5773173E31B2Q24595940-09315980-E638-4713-94E8-80E0684EA121Q24600728-2FA1FAEC-9D69-48EF-8E4D-0F314DD00CBBQ24646296-9619A437-2CDF-4322-AC96-ED4EF2FD0366Q24652941-FE73EB73-7E78-4EEA-8146-36358F8F71E2Q24794295-89CF4D2B-299B-4E7F-AAFA-EC2DF4B30E05Q24801724-FD8E8A07-ABE2-4DDC-9F8A-380A787C7EADQ26745503-536C41A3-187A-4AB5-8352-5A453E09F426Q27000971-9BA774B6-4C91-4D64-9300-1B025E4EB587Q27022231-2291F70A-3635-4966-A8DF-FEDA33390D59Q28079903-9D251709-5BF1-435C-87BB-AE900E15A50EQ28250360-A5F262C4-212E-4CB9-A80E-30EAE0C838CAQ28256222-E26291DE-F808-406C-9AB4-8BE638F1713BQ33289243-65E43FDE-E812-433E-ADAB-D1CC3201F27AQ33632616-07B143E4-DD1C-4F62-8E5A-0CC7063F2B55Q33947462-30E3383F-5447-40BA-BD46-3B3253749068Q34127834-6A59DDA6-202B-42C2-8BF6-DE6F78DADAD2Q34539146-08A38A55-E529-40BF-9D85-15A7F809B5CFQ34677800-5AE56488-6305-4ACB-82F9-46BD01911428Q34891746-3B24310A-14A4-4CEE-A9A5-2D676B0FF64FQ35081240-1432AB23-7853-4795-81E2-43E1DCE0A626Q35103648-5D509215-3B19-4915-B93C-0010FEE03054Q35151326-36215E6D-48B4-4EC5-9AC5-B17B9383498BQ35180333-209F4ECF-89E7-4BE2-BC31-B02E55CFCA54Q35284879-71B9C8CC-559F-4C85-A75C-952DBA307A28Q35381008-0775633A-D2CF-4847-ABB7-63053F2CA121Q35519662-ABE54A8A-F149-4926-80F9-96C46C9BCC18Q35534313-5C9D4C49-73C4-47D8-9947-C199DCEC8995Q35742791-56E07908-0D65-4F79-8391-7997A7C21131Q35777756-6D68358A-8C69-4AEB-B062-E84EEB5153A7Q35957146-808B071F-5AA0-4B9E-A7B9-56120FB79BC8Q36078959-2E7FCB56-5DAF-49DE-B472-8FDC4A988A97Q36239686-2DEC7D97-9AC7-4A16-A969-19CB2F54C690Q36326369-2365A245-F7D9-4D61-8B50-3D8BED0B913DQ36377723-F125E0A3-BF96-4827-BC00-D73F51FFEE2FQ36392145-DD21A2EB-A19C-4AE6-99A5-2823DFA10A50Q36547748-7EAA3AEF-5CAA-488E-81E6-85E228D6B53FQ37107268-9FF95331-7348-4E6D-A94B-ED9912CB8E55Q37139096-AAC1C161-9E3D-454A-9DB4-236D3D798DF0Q37174905-2FB3D7B1-3B2B-46A5-8B2E-EB1B1C5477CA
P2860
Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@ast
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en-gb
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@nl
type
label
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@ast
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en-gb
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@nl
prefLabel
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@ast
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en-gb
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@nl
P2093
P2860
P3181
P356
P1476
Glucose catabolism in cancer c ...... s for the tumor suppressor p53
@en
P2093
P L Pedersen
S P Mathupala
P2860
P304
P3181
P356
10.1074/JBC.272.36.22776
P407
P577
1997-09-05T00:00:00Z